Meet the Alzheimer’s Moonshot Community Members Attending AD/PD
Get to know the StartUp Health companies you can meet at AD/PD, the International Congress on Alzheimer’s and Parkinson’s Disease and Related Neurological Disorders, in Vienna, Austria, from April 1-5, 2025.
Produced by Jennifer Hankin, Gabe Cohen, and Nicole Kinsey
The AD/PD™ Conference is where the brightest minds gather to explore the latest research, clinical trials, and treatments for Alzheimer's and Parkinson's. From uncovering groundbreaking discoveries to sharing the latest developments in treatments. Held in Vienna, Austria, the AD/PD Conference has grown to be the leading event in the field of neurodegenerative disorders with over 4,700 participants from 70+ countries.
Alzheimer’s Moonshot Community Attendees
Meet these StartUp Health Alzheimer’s Moonshot Community members during the conference.
ADmit Therapeutics is building an epigenetic platform for early Alzheimer’s disease detection and intervention. They’ve developed a simple blood test (MAP-AD) that, when paired with the company’s machine learning algorithm, can provide a personalized report of Alzheimer’s progression.
Based in Barcelona, Spain
Learn more | Connect
Alamar Biosciences is revolutionizing biomarker discovery with its NULISA platform, which enables attomolar sensitivity and high-throughput protein quantification using next-generation sequencing. By integrating its proprietary Attobody antibody engineering and ARGO HT automation, the company enhances precision in early disease detection and proteomics research.
Based in Fremont, CA
Learn more | Connect
Cx Precision Medicine is transforming geriatric care with its NeuroFirst Memory blood test, enabling earlier and more accurate detection of neurodegenerative diseases like Alzheimer’s. By leveraging biomarker-based diagnostics, the company empowers primary care physicians to diagnose memory issues sooner for more targeted treatments.
Based in Houston, TX
Learn more | Connect
MindAhead is developing a digital therapy for Alzheimer’s that uses behavioral activation to enhance brain function and quality of life for people with mild cognitive impairment. Their AI-powered app guides users through brain exercises and activities, backed by clinical validation and industry investment.
Based in Berlin, Germany
Learn more | Connect
Neotiv is enhancing early detection and monitoring of Alzheimer’s disease through scientifically-validated digital cognitive assessments. Its platform integrates engaging memory tests with scalable research tools, supporting clinicians and researchers in tracking and studying cognitive decline.
Based in Berlin, Germany
Learn more | Connect
Perceiv AI is using AI to predict Alzheimer’s disease progression and make clinical trials more effective. Their first product, Foresight AD™, forecasts the progression of cognitive decline in Alzheimer’s disease, and in the future they plan to use similar technology to predict the progression of diseases like MS and Parkinson’s.
Based in Montreal, Quebec
Learn more | Connect
Quanterix is revolutionizing biomarker detection with its Simoa technology, enabling early disease diagnosis across oncology, neurology, cardiology, immunology, and infectious disease. Through its Lucent Diagnostics brand, the company advances precision healthcare by uncovering novel biomarkers for prevention and next-generation treatments.
Based in Cambridge, MA
Learn more | Connect
Stata DX is creating the first point-of-care platform for neurology, envisioning a future where monitoring brain health is as simple as checking blood sugar levels. Leveraging patented sensor technology, StataDX is developing the first finger-prick blood testing platform designed to simplify the diagnosis of Alzheimer’s and other neurological conditions, transforming how brain health is monitored and managed.
Based in Boston, MA
Learn more | Connect
Veravas is advancing early detection of Alzheimer’s and neurological diseases with its proprietary VeraBIND technology. Its Tau Screening Test predicts cognitive decline years in advance, using plasma samples and Tau PET imaging for early diagnosis in asymptomatic patients.
Based in Austin, TX
Learn more | Connect
Agenda
Check out these sessions that Alzheimer’s Moonshot Community members are speaking and/or presenting at during the conference.
TUESDAY, APRIL 1
Diagnostics Accelerator (DxA) Day
Pre-Conference Symposium: By Invitation Only
Tuesday, April 1 | 8am-2:30pm CET
Hall F1
Remote and Unsupervised Detection and Monitoring of Memory Decline in Alzheimer’s Disease
1-1:20pm CET
David Berron, PhD
CSO & Co-founder, Neotiv
Accelerating Biomarker Discovery and Diagnostics for Alzheimer’s Disease with the ARGO™ Proteomics Platform
1:40-2pm CET
Yuling Luo, PhD
Chairman, CEO & Founder, Alamar Biosciences
Symptom Detection and Treatment Programs: Health Correlates and Apps
Tuesday, April 1 | 1:15-3:30pm CET
Hall B
Remote and Unsupervised Digital Monitoring of Memory Decline in Patients with Mild Cognitive Impairment
2:30-2:45pm CET
David Berron, PhD
CSO & Co-founder, Neotiv
Effect of MindAhead's Digital Behavioral Activation Therapy on Quality of Life in MCI and Mild Dementia
3-3:15pm CET
Patrick Fissler, PhD
CSO & Co-founder, MindAhead
THURSDAY, APRIL 3
NULISA: Ultra-sensitive & Multiplex Detection of 120+ Protein Biomarkers for CNS Disease
10:40-11:10am CET
Exhibition/Product Theater
Alex Forrest-Hay
SVP, Global Sales, Alamar Biosciences
FRIDAY, APRIL 4
Fluid & Digital Biomarkers & Imaging
1:50-3:50pm CET
Hall E
Alzheimer’s Disease Biomarkers Among Diverse Populations – Findings from the Habs-Hd Study
2:05-2:20pm CET
Sid O’Bryant, PhD
Scientific Founder & Advisory Board Chair, Cx Precision Medicine
SATURDAY, APRIL 5
Fluid Biomarkers & Imaging in AD, PD, LBD, PSP & Small-Vessel Disease
8:40-10:40am CET
Hall F1
Fully Automated Ultrasensitive Simoa Assays for Biomarkers of Alzheimer’s Related Amyloid & Tau Pathology: P-Tau 205 & P-Tau 212
10:10-10:25am CET
Kishore Malyavantham, PhD
Vice President of Research and Development, Quanterix
Call for Innovation
Health Moonshot Communities are exclusive, mission-aligned networks of founders, CEOs, and partners collaborating to solve the biggest health challenges of our time.
Our communities include: Access to Care, Alzheimer’s Disease, Cardiometabolic Health, Children’s Health, End Cancer, Food as Medicine, Mental & Behavioral Health, Oral Health, Type 1 Diabetes, Wellness, Women's Health, and many more.
If you’re mission-driven, collaborative, and ready to contribute as much as you gain, you might be the perfect fit. Learn more and apply today.
Follow us on LinkedIn for daily updates on Health Transformers.
